MIAMI--(BUSINESS WIRE)--Drawing on their clinical and scientific experience, researchers at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center have identified a new strategy for attacking esophageal adenocarcinoma (EAC), one of the most deadly forms of cancer. Their study found that inhibiting one of the key cellular signaling pathways might result in a better response to chemotherapy, with a potential improvement in patient outcomes.
“Our clinicians work closely with our researchers in taking a bedside-to-bench-to-bedside approach to treating EAC patients at Sylvester,” said Alan S. Livingstone, M.D., professor and Chairman of the DeWitt Daughtry Family Department of Surgery and study co-author. “This research lays the foundation for clinical trials using these experimental therapeutics at Sylvester and has the potential to impact clinical care of EAC patients in the near term.”
Help employers find you! Check out all the jobs and post your resume.